WNK2 and neoplasm: It selectively interferes with EGFR receptor tyrosine kinase activity by competing with adenosine triphosphate for the EGFR binding site, thereby inhibiting tumor neovascularization, blocking blood supply to tumor cells, and inhibiting mitogen-activated protein kinase activation and promoting apoptosis.[1,2]